GlassScriptPhysician profile
Eugenia M Guray
NPI 1275506263
$10,105.71
in general payments reported to CMS, 2019-2025
43 companies · $1,491 in 2025
The $1,491 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $764 · 2021: $2,024 · 2022: $1,583 · 2023: $1,545 · 2024: $1,629 · 2025: $1,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,644 · Education: $20.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,644.44 |
| Education | $20.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,803.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,168.84 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,107.02 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $737.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $698.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $527.77 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.69 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $319.32 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $303.61 | 2019-2025 | Spravato |
| Daiichi Sankyo INC. | $281.58 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $256.89 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $246.03 | 2020-2021 | |
| Pfizer INC. | $235.21 | 2021-2025 | |
| Corcept Therapeutics | $215.92 | 2024-2025 | Korlym |
| Mayne Pharma Commercial LLC | $173.29 | 2023-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugenia Guray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.